17 years of research by more than 30,000 people tell you the dangers of eating red meat

Share This Post

The latest shows that a diet without red meat significantly reduces the risk of colon cancer in British women. Researchers at the University of Leeds evaluated whether red meat, poultry, fish or vegetarian diets are associated with colon and rectal cancer risk. When comparing the effects of these diets on the development of cancer in specific subpopulations of the colon, they found that those who frequently ate red meat had a higher percentage of cancers in the distal colon than those without a red meat diet-that is, cancers were found in the distal part of the colon, ie Where to store feces.

The study included 32,147 women from England, Wales and Scotland. They were recruited and surveyed by the World Cancer Research Foundation from 1995 to 1998 and tracked for an average of 17 years. In addition to reporting their dietary habits, a total of 462 cases of colorectal cancer, 335 cases of colon cancer, and 119 cases of distant colon cancer were recorded.

By 2030, it is expected that there will be more than 2.2 million new cases of colorectal cancer worldwide, which is the third most commonly diagnosed cancer among British  women. Previous studies have shown that eating large amounts of red meat and processed meat increases the risk of colorectal cancer. It is estimated that about one-fifth of bowel cancers in the UK are related to eating these meats. This study of more than 30,000 people lasted 17 years, and the results are extremely convincing. How should you prevent colorectal cancer, you should know?

Website |  + posts

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Cancer

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
Blood cancer

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new option for treatment after failure of initial therapies. The approval follows the presentation of data from clinical trials showing that this combination improved patient outcomes. This combination is a new strategy in the management of LBCL and provides a greater number of available treatments for those with few choices.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟